

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION
(PCT Rule 61.2)Date of mailing (day/month/year)
07 November 2000 (07.11.00)To:
Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as elected OfficeInternational application No.
PCT/EP00/02917Applicant's or agent's file reference
WO-02953International filing date (day/month/year)
03 April 2000 (03.04.00)Priority date (day/month/year)
01 April 1999 (01.04.99)

Applicant

BOOIJ, Johannes et al

1. The designated Office is hereby notified of its election made:

 in the demand filed with the International Preliminary Examining Authority on:

12 October 2000 (12.10.00)

 in a notice effecting later election filed with the International Bureau on:2. The election was was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

R. E. Stoffel

Telephone No.: (41-22) 338.83.38

10821
PATENT COOPERATION TREATY**PCT**

REC'D 19 APR 2001

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference WO-02953	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP00/02917	International filing date (day/month/year) 03/04/2000	Priority date (day/month/year) 01/04/1999
International Patent Classification (IPC) or national classification and IPC A61K9/16		
Applicant DSM N.V.		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application</p>		

Date of submission of the demand 12/10/2000	Date of completion of this report 17.04.2001
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Merkel, B Telephone No. +49 89 2399 2138



INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

International application No. PCT/EP00/02917

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-20 as originally filed

Claims, No.:

1-24 as originally filed

Drawings, sheets:

1/1 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- the description, pages:
- the claims, Nos.:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/02917

the drawings, sheets:

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 6-9, 16-24
 No: Claims 1-5, 10-15

Inventive step (IS) Yes: Claims
 No: Claims 1-24

Industrial applicability (IA) Yes: Claims 1-24
 No: Claims

2. Citations and explanations
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/02917

Item V:

D1: EP-A-0 277 008 (BEECHAM GROUP PLC) 3 August 1988 (1988-08-03)
cited in the application

D2: EP-A-0 118 196 (PFIZER INC.) 12 September 1984 (1984-09-12)

D3: WO 98 21212 A (GIST-BROCADES B.V.) 22 May 1998 (1998-05-22)

D4: WO 97 47301 A (SMITHKLINE BEECHAM CORPORATION) 18 December 1997 (1997-12-18)

Claim 1 refers to agglomerates in crystalline form comprising one or more β -lactam compounds, with the proviso that the rosette-like crystalline form of potassium clavulanate is excluded. In other words, it refers to all crystalline agglomerates of β -lactam compounds other than the rosette-like crystalline form of potassium clavulanate. Therefore said claim also comprises subject-matter known in the art. D1 discloses on page 2, lines 15-17 that crystalline potassium clavulanate exists sometimes agglomerated into plate-like crystals and sometimes randomly aggregated into loosely formed bundles. In claim 1 of the pending application the excipient is merely optional and the term "high water affinity" is vague and moreover is fulfilled by the compound potassium clavulanate.

Also the process claimed in the pending application cannot be distinguished from the process disclosed in D1. Let apart that the mere stirring of a β -lactam compound in a liquid phase as defined in claim 10 will not produce agglomerates, D1 already discloses the use of solvents and non-solvents for precipitation of the β -lactams.

Therefore claims 1-5 and 10-15 are regarded to not fulfil the requirements of novelty.

The further claims do not appear to contain additional features which might be the basis for inventive step as they refer to process steps or additional ingredients frequently used in the conditioning of drugs.

A claim must contain all features necessary that a skilled person can carry out an invention and all features necessary to distinguish the claimed subject-matter from the

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/02917

process disclosed in the prior art. In other words, the claim must contain the process steps which are responsible that a different product compared to the rosette-like crystalline form of D1 is obtained. This is not the case in the claims of the application-in-suit.

With respect to inventive step also D3 has to be taken into account wherein it is stated on page 4, lines 11-18 that a small amount of water can influence the crystal morphology of the final product.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 9/16, 31/424		A3	(11) International Publication Number: WO 00/41478 (43) International Publication Date: 20 July 2000 (20.07.00)
<p>(21) International Application Number: PCT/EP00/02917</p> <p>(22) International Filing Date: 3 April 2000 (03.04.00)</p> <p>(30) Priority Data: 99201034.8 1 April 1999 (01.04.99) EP</p> <p>(71) Applicant (for all designated States except US): DSM N.V. [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BOOIJ, Johannes [NL/NL]; Bos en Duinplein 10, NL-2061 VS Bloemendaal (NL). LEFFERTS, Ageeth, Geertruida [NL/NL]; Henri 't Sasplein 10, NL-4535 RG Breda (NL).</p> <p>(74) Agents: VISSER-LUIRINK, Gesina et al.; DSM N.V., DSM Patents & Trademarks, Office Delft (994-0760), P.O. Box 1, NL-2600 MA Delft (NL).</p>		<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Upon the request of the application, before the expiration of the time limit referred to in Article 21(2)(a).</p> <p>(88) Date of publication of the international search report: 2 November 2000 (02.11.00)</p>	
<p>(54) Title: AGGLOMERATES BY CRYSTALLISATION</p> <p>(57) Abstract</p> <p>The present invention describes novel agglomerates in crystalline form of β-lactam compounds. Furthermore, a process for the preparation of said agglomerates, wherein a solution or suspension of at least one β-lactam compound in a solvent is mixed with one or more anti-solvents has been described.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/02917A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/16 A61K31/424

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EP0-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 277 008 A (BEECHAM GROUP PLC) 3 August 1988 (1988-08-03) cited in the application page 1, line 1 -page 5, line 42	1-24
A	EP 0 118 196 A (PFIZER INC.) 12 September 1984 (1984-09-12) page 1, line 1 -page 5, line 13	1-24
A	WO 98 21212 A (GIST-BROCADES B.V.) 22 May 1998 (1998-05-22) page 4, line 11 - line 18	1-24
A	WO 97 47301 A (SMITHKLINE BEECHAM CORPORATION) 18 December 1997 (1997-12-18) page 2, line 19 - line 31 page 5, line 4 - line 28	1-24

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

12 July 2000

19/07/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Appl. No.

PCT/EP 00/02917

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 277008	A 03-08-1988	AT 399154 B AT 16388 A AU 620538 B AU 1092788 A BE 1000734 A CA 1326486 A CH 677671 A DE 3853962 D DE 3853962 T DK 40488 A ES 2008418 A ES 2074048 T FR 2610196 A GB 2200355 A,B GR 88100031 A,B IT 1227072 B JP 2648321 B JP 63270687 A JP 2716966 B JP 9169771 A KR 9604535 B LU 87123 A NZ 223316 A PT 86631 A,B US 5679789 A US 5750685 A US 5288861 A ZA 8800583 A		27-03-1995 15-08-1994 20-02-1992 04-08-1988 21-03-1989 25-01-1994 14-06-1991 20-07-1995 08-02-1996 30-07-1988 16-07-1989 01-09-1995 05-08-1988 03-08-1988 16-12-1988 14-03-1991 27-08-1997 08-11-1988 18-02-1998 30-06-1997 06-04-1996 03-05-1988 27-10-1989 01-02-1988 21-10-1997 12-05-1998 22-02-1994 30-11-1988
EP 118196	A 12-09-1984	US 4456753 A AT 24515 T AU 541675 B AU 2420984 A CA 1190220 A DE 3461802 D DK 51784 A,B, ES 529485 D ES 8504700 A FI 840475 A,B, GR 81694 A HK 99687 A HU 34208 A,B IE 56752 B IL 70872 A JP 1918358 C JP 6043429 B JP 59148789 A KE 3755 A KR 8701071 B NZ 207038 A PH 19052 A PL 246090 A PT 78058 A,B SG 70087 G YU 20684 A ZA 8400853 A		26-06-1984 15-01-1987 17-01-1985 16-08-1984 09-07-1985 05-02-1987 08-08-1984 01-05-1985 16-07-1985 08-08-1984 12-12-1984 31-12-1987 28-02-1985 04-12-1991 31-08-1987 07-04-1995 08-06-1994 25-08-1984 02-10-1987 27-05-1987 09-05-1986 11-12-1985 13-02-1985 01-03-1984 19-02-1988 30-06-1986 25-09-1985
WO 9821212	A 22-05-1998	AU 5551698 A		03-06-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

Joint Application No

PCT/EP 00/02917

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9821212	A	CN	1238776 A	15-12-1999
		EP	0937084 A	25-08-1999
		NO	992225 A	07-05-1999
		PL	333247 A	22-11-1999
WO 9747301	A	18-12-1997	AU 712904 B	18-11-1999
			AU 3392797 A	07-01-1998
			CN 1227488 A	01-09-1999
			CZ 9804072 A	12-05-1999
			EP 0918520 A	02-06-1999
			NO 985824 A	10-02-1999
			PL 330639 A	24-05-1999

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification : Not classified		A2	(11) International Publication Number: WO 00/41478 (43) International Publication Date: 20 July 2000 (20.07.00)
(21) International Application Number: PCT/EP00/02917 (22) International Filing Date: 3 April 2000 (03.04.00) (30) Priority Data: 99201034.8 1 April 1999 (01.04.99) EP		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): DSM N.V. [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): BOOIJ, Johannes [NL/NL]; Bos en Duinplein 10, NL-2061 VS Bloemendaal (NL). LEFFERTS, Ageeth, Geertruida [NL/NL]; Henri 't Sasplein 10, NL-4535 RG Breda (NL). (74) Agents: VISSER-LUIRINK, Gesina et al.; DSM N.V., DSM Patents & Trademarks, Office Delft (994-0760), P.O. Box 1, NL-2600 MA Delft (NL).		Published <i>Upon the request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a). Without international search report and to be republished upon receipt of that report. Without classification; title and abstract not checked by the International Searching Authority.</i>	
(54) Title: AGGLOMERATES BY CRYSTALLISATION			
(57) Abstract The present invention describes novel agglomerates in crystalline form of β -lactam compounds. Furthermore, a process for the preparation of said agglomerates, wherein a solution or suspension of at least one β -lactam compound in a solvent is mixed with one or more anti-solvents has been described.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

AGGLOMERATES BY CRYSTALLISATION

5

Field of the invention

The present invention describes agglomerates of β -lactam compounds in crystalline form and a process to prepare the same.

10

Background of the invention

β -Lactam antibiotics constitute the most important group of antibiotic compounds, with a long history of clinical use. Among this group, the prominent ones are the penicillins and cephalosporins.

15 Presently, most of the β -lactam antibiotics used are prepared by semi-synthetic methods. These β -lactam antibiotics are obtained by modifying a β -lactam product obtained by fermentation by one or more reactions.

20 Clavulanic acid and its alkaline metal salts and esters, another type of β -lactam compound than the penicillin and cephalosporin, act as β -lactamase inhibitors, able to enhance the effectiveness of penicillins and cephalosporins. Clavulanic acid has been applied therefore in pharmaceutical compositions to prevent inactivation of β -lactam antibiotics. For example, the antibacterial activity profile of amoxicillin is enhanced by the use of potassium clavulanate as β -lactamase inhibitor. A combination preparation of amoxicillin trihydrate 25 with potassium clavulanate (Augmentin[®]) is well known.

It is generally known that antibiotic compounds in powder form are not suitable for formulation purposes, because generally these powders perform 30 badly as far as flowability is concerned which causes problems in the manufacturing of final dosage forms, such as tablets. Accurate dosing of the several ingredients is needed to ensure constant end product quality. In case of poor flowabilities, such accurate dosing is difficult to guarantee. Also, the needle shaped crystals, such as of potassium clavulanate, often show a low

bulk density. Thus, the contribution of such crystals to the overall volume of the final dosage form is relatively high.

To overcome these problems, often granules of compounds, for example potassium clavulanate with excipients (such as microcrystalline cellulose like Avicel® or silica like Syloid® or Aerosil®) or granules of composition, for example potassium clavulanate with other active ingredients like amoxicillin trihydrate are made before producing the final formulation. Several processes are known to form such granules. For example, in case of wet granulation, potassium clavulanate can be mixed with, for instance, amoxicillin and a binding agent after which the mixture is moistened by a solvent, granulated and bounded. Before tabletting the granules with excipients, the granulates might be sieved. This wet granulation process is economically unattractive, as it uses solvents which must be recovered and/or recycled. It is labour intensive, expensive and time consuming due to the large number of processing steps such as mixing, granulating, sieving, drying etc. Moreover, in case of unstable β -lactam compounds such as potassium clavulanate, wet granulation is problematic due to the use of a solvent and high temperature during the drying step of the process.

Another method to granulate poor flowing powders is dry granulation. As an example, the slugging process can be mentioned as described in International patent applications WO 9116893 and WO 9219227. Here, tablets of the poor flowing material with excipients are made and subsequently broken again and sieved to produce granules. Another example of dry granulation is the compaction process as described in International patent application WO 9528927. In this application, a process has been mentioned wherein compacted granules of a β -lactam antibiotic, for example amoxicillin, and a mixture of an active β -lactam antibiotic and a secondary pharmaceutically active agent, for example potassium clavulanate with excipients are made using roller compacting. Subsequently, the roller compacted flakes are milled, resulting in granules which can be mixed with excipients to press the final tablets. An advantage compared to the wet

granulation is the absence of solvents. However, the dry granulation is relatively time consuming due to a large number of processing steps. Also, in case of unstable products, a quality risk exists due to locally high temperatures in the process, e.g. due to abrasion. In case the material is 5 hygroscopic, such as potassium clavulanate, another disadvantage is the handling of the dried crystals before and during the granulation process. During this handling, the product might attract water leading to unwanted degradation reactions. Also a major disadvantage of roller compacted products is the relatively large amount of fines which should be removed using sieving 10 techniques to improve the flowability of such products.

Furthermore, difficulties one may encounter by using dry granulation are:

- a lot of dust is produced during the slugging or roller compaction process and in some cases, for example such as amoxicillin, this dust sticks to the coarser particles and can not be separated by currently applied vibrating 15 sieves,
- dust may deteriorate the flow properties of agglomerates,
- dust is also responsible for air born β -lactam antibiotics particles which can cause allergic reaction.

Granules of the active ingredient in the presence of excipients are 20 produced by the process mentioned above. It would be advantageous to have the possibility to produce granules of the pure active ingredient. In that case, the production process can be more flexible and possibly overall less excipients are necessary. Also the production of final dosage forms will be more flexible. In case of hygroscopic substances such as potassium 25 clavulanate, however, it will be difficult to granulate using one of the above processes without the presence of excipients like microcrystalline cellulose or silica, as the latter are known to protect the hygroscopic potassium clavulanate by removing the free water from it and, thus, keeping the water activity of such compositions low. However, in the International patent 30 application WO 9733564 a method has been mentioned in which granules of a pure active ingredient, without the presence of excipients, are made by

extrusion. Here, a paste is made of the crystalline powder by adding a liquid wherein the powder is insoluble or slightly soluble. The paste is needed then and extruded in a double screwed extruder, after which the granules are dried. The process again is not suitable for unstable products, as locally the 5 temperature in the extruder is high (up to 80°C). Also, this wet material should be dried at elevated temperatures.

Another method to improve the flowability of needle shaped crystals, especially in the case of potassium clavulanate, is to agglomerate them during crystallisation to the so-called rosette form as described in European patent EP 10 277008 B1. In this case, a plurality of needle crystals radiate out from a common nucleation point. The rosettes show an increased flowability compared to the needles. However, a large disadvantage of these types of 15 granules is the inclusion of impurities, leading to a decreased chemical quality of the product. Also, the included impurities probably increase the degradation rate of the β -lactam compound, thus resulting in an even worse chemical quality during storage.

The object of the invention is to provide a valuable form of a β -lactam antibiotic compound and a process to prepare such a compound that overcomes most of the above mentioned disadvantages.

20 Surprisingly, it has been found that novel agglomerates in crystalline form of β -lactam antibiotics in a liquid phase are produced through a crystallisation process when a solution of at least one β -lactam compound in a solvent or in a mixture of solvents under stirring is mixed together with one or more anti-solvents. Preferably, one or both solutions contain water.

25

Description of the Figure

An Electron-microscope photo of potassium clavulanate agglomerates as prepared according to Example 9 is shown in the Figure.

30

Summary of the invention

The present invention provides agglomerates in crystalline form comprising one or more β -lactam compounds having at least one β -lactam compound of a high water affinity, and optionally contain one or more excipients. Preferably, said agglomerates comprise clavulanic acid or a pharmaceutically acceptable salt thereof like potassium clavulanate. Further, the agglomerates comprising potassium clavulanate may contain amoxicillin as the active β -lactam antibiotic compound. The term agglomerate refers to clustering of the crystals of a compound.

The excipients are microcrystalline cellulose, preferably Avicel[®], or silica, preferably Sylloid[®] or Aerosil[®].

The said agglomerates can also be of sterile form.

The new agglomerates are of an average particle size between about 1 μm and 1500 μm , preferably between about 500 μm and 1500 μm , more preferably between 800 μm and 1200 μm , or between 1 μm and 300 μm , preferably between 1 μm and 200 μm .

Moreover, the agglomerates of the present invention are substantially free from non-agglomerated β -lactam crystals, for instance, non-agglomerated crystals having a weight percentage between 0-10%.

Furthermore, a process to prepare said agglomerates has been provided for. The agglomerates are produced in a liquid phase medium, which process involves mixing together a solution or suspension of at least one β -lactam compound corresponding to the β -lactam compound to be prepared in agglomerate form in a solvent or in a mixture of solvents under stirring with one or more anti-solvents, whereby at least one of both solvents and co-solvent contains water. The overall weight ratio of the solution containing the β -lactam compound to anti-solvent is about 0.05 to 10%. The solvent is for instance water or ethanol and the anti-solvent a ketone, like acetone, methylethylketone, methylisobutylketone or an ester, like methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate or an alcohol, like 1-propanol,

1-butanol, 2-butanol, 2-methyl-1-propanol or a mixture of these solvents. The pH of the solution of the β -lactam compound may be adjusted to neutral. Preferably, the solvent is water or ethanol and the anti-solvent is acetone or ethyl acetate with some water present in at least the solvent or the anti-solvent. It is possible also to add other ingredients in one of the streams (solvent, anti-solvent or mixture thereof), either suspended or dissolved.

During the preparation of the agglomerates, one or more stirring devices are used to crystallise, agglomerate and deagglomerate, or to crystallise and agglomerate, or to crystallise and deagglomerate the β -lactam compound and optionally classification and blending with excipients and/or another β -lactam compound in a batch or continuous operation in one or more reaction vessels or in one integrated step. Furthermore, the operation is performed by applying stirring devices in one or more vessels, in-line mixers or a combination thereof. Furthermore, it is possible to use a high shear mixer during the preparation of these agglomerates. Also, agglomerates with various particle sizes can be prepared by using a nozzle-sprayer for the β -lactam containing solution.

The agglomerates of various particle sizes are regulated by further using a combination and permutation of different stirring devices and their speed, the type and amount of the solvents used and the way of mixing of the solvents.

Agglomerates of potassium clavulanate of the present invention show a good level of stability and hygroscopicity.

The agglomerates, prepared according to the present invention, with one or more pharmaceutical acceptable excipients are suitable for pharmaceutical formulations.

Pharmaceutical formulations comprising amoxicillin, preferably amoxicillin trihydrate and the crystalline agglomerates of potassium clavulanate of the present invention and optionally one or more pharmaceutically acceptable inert excipients form another aspect of the present invention.

Also, a pharmaceutical formulation, comprising crystalline agglomerates of amoxicillin trihydrate and potassium clavulanate and one or more pharmaceutically acceptable inert excipients can be made.

The agglomerates, prepared according to the present invention, are suitable to prepare oral dosage forms such as tablets, capsules, syrups or sachets, dry instant or ready to use in multiple or single dose form. According to another embodiment of the invention, the oral dosage form, comprising agglomerates or granules of amoxicillin with or without one or more excipients can also contain a β -lactamase inhibitor such as potassium clavulanate, preferably in the agglomerated form. Said agglomerates can also be used in Dose Sipping devices.

Detailed description of the invention

The present invention provides economically interesting agglomerates in crystalline form of a β -lactam compound. The β -lactam compounds are for instance clavulanic acid but one can also think of amoxicillin or ampicillin. The compound can be in the salt form, such as amine or alkaline metal salt. Preferably, agglomerates of potassium clavulanate are produced.

The agglomerates of said invention have an average particle size between about 1 μm and 1500 μm , preferably between about 500 μm and 1500 μm , more preferably between 800 μm and 1200 μm , or between 1 μm and 300 μm , preferably between 1 μm and 200 μm .

Furthermore, said agglomerates are preferably substantially free from non-agglomerated β -lactam crystals, as for instance in the needle form. By substantially free from non-agglomerated crystals is meant that the agglomerates have a weight percentage between 0-10% of non-agglomerates.

A process for the preparation of the agglomerates, wherein one or more β -lactam compounds with or without excipients are used, consists of a crystallisation procedure to build up agglomerates. The process comprises mixing together a solution or suspension of one or more β -lactam compounds

corresponding to the agglomerates to be produced in a solvent or in a mixture of solvents with one or more anti-solvents under stirring. The combination of solvent and anti-solvent can result in an emulsion. In the solvent or anti-solvent an amount of water should be present, for instance in an amount of 5 0.05 to 10%. Thereafter, the agglomerates are filtered off, washed and dried. The agglomerates, thus produced in high yield, maintain the quality criteria set and are highly suitable for further processing. For the present application, a anti-solvent is defined as a liquid in which the β -lactam compound does not dissolve or dissolves only poorly.

10 More in detail, the β -lactam compound, for instance potassium clavulanate, is dissolved or suspended in an appropriate solvent or a mixture of (partly) miscible solvents, such as water, alcohols, like ethanol, methanol, 1-propanol, 2-butanol, 2-methyl-propanol, ketones, like acetone, methylethylketone, methylisobutylketone, or an ester, like methyl acetate, ethyl acetate, butyl acetate, with at least a small amount of water present. 15 Sometimes an emulsion is formed during the agglomeration process. Optionally, the pH of the solution is adjusted to about neutral, namely to pH 5.0-7.5 by adding an acid, as for instance acetic acid or ethylhexanoic acid. The way of dissolution will be known to those skilled in the art and will 20 depend on the stability of the β -lactam compound in the solvent or in a mixture of solvents. In case water is used as the only solvent for the dissolution of potassium clavulanate, residence time and temperature should be as low as possible and a technique such as in-line mixing, for example a static mixer, can be attractive. If for example acetone is present, a residence 25 time of several hours might be acceptable.

30 The β -lactam compound, for example potassium clavulanate, present in the solvent dissolved or in suspension or in both forms, is contacted with a anti-solvent such as ketone, like acetone, methylethylketone, methylisobutylketone, or an ester, such as methyl acetate, ethyl acetate, butyl acetate or a mixture thereof, or an alcohol such as 1-propanol, 2-butanol, 2-methyl-propanol optionally containing a solvent for the β -lactam compound,

such as water or an alcohol, like methanol or ethanol for potassium clavulanate. The overall weight ratio of the solution containing the β -lactam compound to the anti-solvent depends on the combination of solvents and on the desired agglomerate diameter, but generally lies within 0.05-10%. Also, it
5 is possible to adjust this ratio by adding some solvent to the crystalliser before or during the process. This ratio will influence the average diameter of the agglomerates: the higher the relative volume of the solvent, the larger the agglomerates will be.

Several methods of mixing can be applied and will be known to those
10 skilled in the art. For example, the solution of the β -lactam compound, for instance a potassium clavulanate solution and the anti-solvent can be added simultaneously to the crystalliser or the solution of the β -lactam compound, for instance a potassium clavulanate solution can be added to the anti-solvent or the anti-solvent can be added to the solution of the β -lactam compound, for
15 instance a potassium clavulanate solution. The temperature should be kept below 50°C. The use of seeding material can also be advantageous to enhance the agglomeration process.

The method of contacting the potassium clavulanate containing solution and the anti-solvent can be controlled *via* specific equipment, such as spray
20 nozzles or capillaries. This contacting can occur in a vessel or in line or in a recycling loop over the vessel. It is also possible to first form droplets of solution of a certain diameter, after which the droplets are contacted with the anti-solvent.

Parameters such as the amount of nozzles, their diameter, the flow
25 through the nozzles and the rotational speed of the mixer can be used to control the average particle size and density. In this way, several grades of agglomerates can be produced, with different physical properties.

The method of agitation is determined by the desired agglomeration size
30 of the β -lactam compound. In case of relatively large agglomerates (order of magnitude of 1000 μm), the agitation should be moderate. For example a common turbine agitator or pitched blade agitator can be used. Here, the

general scales up parameters for agitation apply: the diameter of the blades versus the diameter of the vessel should be between 0.2-0.9, preferably between 0.2-0.5, depending on the type of agitator used. The rotational speed (and thus shear), tip velocity, the size of the nozzle sprayer and power input determine the agglomerate size and density and can be used as control parameters. In case the desired agglomerate diameter is small, for example 50-100 μm , high speed agitators, such as toothed disks or rotor-stator mixers with multiple stage mixing/shearing action can be used. It is also possible to use in-line high shear mixers, with the advantage of short residence times. If needed, a recycle loop can be applied over such an in-line system. Another possibility is to combine a moderate shear mixer with a high shear mixer or a mill. For example, agglomerates with a diameter of the order of a magnitude of 1000 μm can be deagglomerated during the crystallisation using a high shear mixer, which is situated in the same crystalliser (such as mounted in the bottom) or as a separate unit after the crystalliser. Also, for example a colloid mill can be placed after the crystalliser for the same purpose. Moreover, the simultaneous crystallisation/agglomeration technique can be combined using ultrasonic crystallisation. This technique has been described for instance in *Pharmaceutical Technology Europe*, 9(9), 78 (1997). In this way different grades concerning particle size distribution, density, porosity and flowability can be easily achieved.

Generally, the residence time in the crystalliser and/or deagglomerator is determined by the desired average diameter of the agglomerates. For purposes of precipitation/crystallisation, long ageing times are not needed, as the crystals are formed immediately after contact with the anti-solvent. For agglomeration and deagglomeration, however, a certain minimum and maximum residence time will be valid, depending on parameters such as mixing time and volume of the vessel.

One of the embodiments of the invention is to have the excipients included in the agglomerates by addition of the same before, after or during the precipitation and/or agglomeration, such as cellulose, preferably

microcrystalline cellulose, more preferably with a water activity < 0.2 at 25°C, most preferably Avicel® PH112. Also, amorphous silica (Syloid®) or colloidal silicon dioxide (Aerosil®) can be used as excipient. All methods of mixing are possible: for example the excipient can be added before, 5 simultaneously or after the addition of the β -lactam compound solution or (partly) suspension to the crystalliser. The excipients can be added as dry matter, suspended or dissolved in a solvent, preferably one of the solvents (or a mixture thereof) which is already used in the agglomeration process. An extra advantage of the addition of such excipients is the positive influence on 10 the agglomeration formation, as they can act as some kind of seeding material.

Another embodiment of the present invention is that the crystallisation and agglomeration can occur in the presence of another active β -lactam ingredient, for example amoxicillin trihydrate besides potassium clavulanate. 15 The amoxicillin can either be added as a solution or suspension leading to co-crystallisation, similar to the agglomeration in the presence of excipients.

The agglomerates of the present invention are not of the rosette type: they consist of small crystals clustered together in a random order (see the Figure). Depending on the method of agitation, method of addition and 20 amount of water, the agglomerate size can easily be adjusted between about 1 and 1500 μm and also relatively small particles as with an average size of 100 μm or relatively large particles with an average size of 1000 μm may be prepared. Compared to, for example, dry compaction, the amount of fines that either must be discharged of or that must be recycled, is small. The 25 agglomerates can easily be separated by for example, filtration or centrifugation and subsequently dried using conventional methods such as tumbling drying. It is also possible to include a classification process. For example, agglomerates of the desired size can be selectively removed from the crystalliser using gravity and/or a sieve. Fines or large particles which can 30 be removed by sieving as well, can be recycled, either by addition in suspension or solution to the next batch.

If necessary, pH-adjustment in order to adapt the pH of the end product can be achieved by adding an acid or base to the solution or the anti-solvent before contacting the streams of solvents containing the β -lactam compound and the anti-solvent. Also, acid or base can be added during the precipitation/crystallisation/ agglomeration process or even after the process.

Surprisingly, the process of the present invention produces agglomerates with a high bulk density, an improved flowability and less compressibility, which can be regulated. For example, potassium clavulanate agglomerates produced can have a loose bulk density between about 0.20 and 0.60 and a tapped bulk density between about 0.50 and 0.90 g/ml and a compressibility between about 10 and 40%.

Due to the excellent flowability of the agglomerates prepared using the above method, they can be used for, for example, direct compression of tablets without the need for further pre-granulation. Moreover, due to the decreased surface area of the agglomerates, the degradation caused by chemical reactions on the surface (e.g. with water) may be reduced. The level of impurities in the agglomerates is also equal to or even lower than in case of conventional needles type crystals. As the bulk density increases significantly, large advantages can be achieved in the transportation as well as in the tabletting process: the final tablet volume can decrease significantly when using agglomerates compared to using needles.

The energy consumption of the present process is low, as the crystallisation process which is commonly present in the down stream process of pharmaceuticals can be combined with the agglomeration process. Moreover, it is possible to combine the usual operations comprising purification and separation by precipitation or crystallisation, agglomeration and deagglomeration, classification and blending with e.g. excipients in one unit. The temperatures can be kept below 50°C during the complete agglomeration process, excipients-free agglomerates can be produced and handling of dry solids before the granulation does not occur, which is an important advantage in case of hygroscopic materials. The solvents needed

for the agglomeration can easily be recycled, possibly without the need for purification. Moreover, the possibility to make pure agglomerates of an unstable and hygroscopic product such as potassium clavulanate is highly attractive.

5 The agglomerates of the present invention can be used for all formulations to produce chew, swallow, disperse, effervescent or normal tablets of all sizes, forms and weights, also to fill hard gelatine capsules and to formulate dry syrups and for administering drugs with the help of a dose sipping device. These agglomerates can also be used, for instance, in a pharmaceutical 10 composition as a tablet of amoxicillin trihydrate produced from agglomerates of amoxicillin trihydrate and potassium clavulanate. For the preparation of sterile agglomerates, the solution of the β -lactam compounds, solvent and anti-solvent are steriley filtered prior to crystallisation/agglomeration. Also, the sterile 15 agglomerates substantially free of non-agglomerates, form another aspect of the present invention.

The invention will now be described with reference to the following Examples, which are not to be construed as being limiting on the invention, and are provided purely for illustrative purposes.

20

Example 1

Preparation of agglomerates of potassium clavulanate (batch process).

25 In a 5-litre flask equipped with a mechanical stirrer, a thermometer and inlet for nitrogen, 4 litres of acetone were placed. A solution of potassium clavulanate (60 g.) in a mixture of water/acetone (120 g, 1:1 w/w) was added in 30 min at 20°C under stirring.

The solid material was filtered off and dried in vacuum at 30°C during 2-3 hours to give agglomerates of potassium clavulanate with an average diameter in the range of 100-1000 μm and a yield of 98%.

30

Example 2**Preparation of agglomerates of potassium clavulanate (semi-continuous process).**

5 In a 2-litre flask equipped with a mechanical stirrer, a thermometer and inlet for nitrogen, acetone (1000 ml) and water (10 ml) were placed. Simultaneously a solution of potassium clavulanate (60 g) in a mixture of water/acetone (120 g, 1:1 w/w) and acetone (4000 ml) was added in about one hour, while agitating.

10 During the addition the content of the vessel was kept at about 1800 ml by periodically removing suspension through an outlet. Thereafter, the solid material was filtered off, washed with dry acetone and dried in vacuum at 30°C during 2-3 hours to yield potassium clavulanate agglomerates with an average diameter in the range of 500-1500 μm .

Preparation of agglomerates of potassium clavulanate by using a turbine stirrer without baffles in the reaction vessel.

20 Acetone (300 ml) and water (3 ml) were placed in a glass cylinder (100 mm in diameter, 150 mm height) equipped with a turbine stirrer (40 mm diameter), a two dropping funnel and a nitrogen inlet tube. Under stirring (900 rpm) simultaneously a solution of potassium clavulanate (30 g) in a water/acetone mixture (60 g, 1:1 w/w) and acetone (2000 ml) were added.

25 During the addition, the contents of the vessel were kept at about 900 ml by removing a part of the contents with the help of an outlet. After the completion of the additions, the solid material was filtered off, washed with dry acetone and dried in vacuum at 30°C. Agglomerates of potassium clavulanate with an average particle diameter of 1000 μm were obtained in 30 98% yield.

Example 4**Preparation of agglomerates of potassium clavulanate by using turbine stirrer with baffles in the reaction vessel.**

5 The experiment was repeated as described in Example 3, but using a vessel with four baffles with a width of 10 mm. Potassium clavulanate agglomerates with an average diameter in the range of 500-1000 μm were obtained.

10

Example 5**Preparation of agglomerates of potassium clavulanate by using a Ultra-Turrax mixer.**

15 Acetone (500 ml) and water (5 ml) were placed in an one litre 4-necked round-bottom flask equipped with a thermometer, Ultra-Turrax mixer (type T25 and shaft S25N-18G), two dropping funnels and a nitrogen inlet tube.

20 Under mixing (8000 rev/min) simultaneously a solution of potassium clavulanate (30 g.) in a water/acetone mixture (60 g. 1:1 w/w) and acetone (2000 ml) was added in one hour at 15-20°C. During the addition, the contents of the vessel were kept between 700 and 800 ml by removing a part 25 of the content with the help of an outlet.

25 After the completion of the additions, the solid material was filtered off, washed with acetone and dried in vacuum at 30°C. Agglomerates of potassium clavulanate with an average diameter in range of 50-250 μm were obtained.

Example 6**Preparation of agglomerates of potassium clavulanate by using Silverson L4RT mixer.**

30

The experiment was repeated as described in Example 5, but using a rotor-stator type high shear mixer (Silverson mixer with emulsion screen, i.e. a screen with spherical pores of about 1.5 mm) at 3000 rev/min.

5 Agglomerates of potassium clavulanate with an average diameter in the range of 10-200 μm were obtained.

Example 7

Preparation of agglomerates of potassium clavulanate in ethyl acetate.

10 Ethylacetate (400 ml) and water (1 ml) were placed in a glass cylinder (100 mm in diameter, 150 mm height) equipped with a turbine stirrer (40 mm diameter), a two dropping funnel and a nitrogen inlet tube. Under stirring (900 rpm) at the same time a solution of potassium clavulanate (10 g) in water (10 ml) and ethyl acetate (600 ml) were added.

15 After the completion of the additions the solid was filtered off, washed with dry ethyl acetate and dried in vacuum at 30°C to give agglomerates with an average diameter in the range of 500-1500 μm .

Example 8

20

Comparison of agglomerates and needles of potassium clavulanate, optionally mixed with Avicel PH112.

25 The agglomerates of potassium clavulanate were prepared as described in Example 6, but using a Silverson mixer with general purpose disintegrating screen, i.e. a screen with square holes with a diameter of about 2.5 mm. In a 2- litre flask equipped with the Silverson mixer, a thermometer and inlet for nitrogen acetone (1000 ml) and water (10 ml) were placed. Under mixing (3400 rev/min) simultaneously a solution of potassium clavulanate (120 g) in a mixture of water/acetone (240 g, 1:1 w/w) and acetone (8000 ml) were 30 added at 15-20°C. During the addition the contents of the vessel was kept at about 1800 ml with an outlet. After completion of the additions the solid was

filtered off, washed with acetone and dried in vacuum at 30°C during 2-3 hours to give agglomerates with an average diameter in the range of 40-200 μm .

Needles of potassium clavulanate were prepared by suspending 5 diclavulanate salt of bis(2-dimethylaminoethyl) ether (100 g) in acetone (3350 ml) and water (50 ml). Under stirring a solution of potassium 2-ethylhexanoate (1450 ml, 0.34 M) in acetone at 5-10°C was added. After 1 hour stirring the mixture was filtered off, washed with dry acetone and dried in vacuum during 18 hours at room temperature to give 81.2 g of potassium 10 clavulanate needles.

A comparison of physical properties of potassium clavulanate in agglomerated and needle form, optionally mixed with Avicel PH112 in a ratio of 70 : 30 w/w% have been described in Table 1.

15 Table 1: Comparison of physical properties of potassium clavulanate in agglomerated and needle form, optionally mixed with Avicel PH112

Material	Loose bulk density	Tapped bulk density	Compressibility	Particle size distribution
Agglomerates of potassium clavulanate	0.49g/ml	0.68g/ml	28%	between 1 and 200 μm
Needles of Potassium clavulanate	0.18g/ml	0.36g/ml	50%	between 5 and 75 μm
Agglomerates of potassium clavulanate mixed with Avicel PH112	0.43g/ml	0.61g/ml	29%	Not determined
Needles of potassium clavulanate mixed with Avicel PH112	0.20g/ml	0.40g/ml	50%	Not determined

Example 9

20 Preparation of agglomerates of potassium clavulanate in acetone/water at a speed of the agitator of 3000 RPM.

A solution of potassium clavulanate was made by dissolving circa 5 kg of potassium clavulanate in 10 l aqueous acetone (acetone:water = 50:50 w/w). This solution, which was kept at 5°C was pumped through a 0.9 mm nozzle to a crystalliser equipped with a high shear mixer and containing 50 l of acetone. Simultaneously, acetone was added to the crystalliser with a volume ratio compared to the solution of circa 21. During the process, the rotational speed of the agitator was 3000 RPM and the temperature was circa 15°C. The agglomerated suspension was removed continuously from the crystalliser, centrifuged, washed with dry acetone and dried in vacuum at 30°C. In this way, agglomerates such as shown on the Figure were produced with a loose bulk density of 0.22 g/ml, a tapped bulk density of 0.30 g/ml and a compressibility of 27%. The particle size distribution is given in Table 2 and a photo made by an Electron-microscope of potassium clavulanate is shown in the Figure.

15

Table 2: Particle size distribution [volume %]

<75 µm	75-150 µm	150-250 µm	250-500 µm	500-710 µm	> 710 µm
46.3	43.3	8	1	0.2	0.1

Example 10

20

Influence of the agitator speed during agglomeration on the physical properties of the agglomerates.

A solution of potassium clavulanate was made by dissolving circa 10 kg of potassium clavulanate in 20 l aqueous acetone (acetone:water = 50:50 w/w). This solution, which was kept at 5°C was pumped through a 2.5 mm nozzle to a crystalliser equipped with a high shear mixer and containing 40 l of acetone. Simultaneously, acetone was added to the crystalliser with a volume ratio compared to the solution of circa 22. During the process, the rotational speed of the agitator was increased from 1000 RPM to 2000 RPM and the temperature was circa 15°C. Continuously, the suspension was removed from

the crystalliser using a pump. The two agglomerated suspensions made were centrifuged, washed with dry acetone and dried in vacuum at 30°C. The physical properties can be seen in Table 3.

5 Table 3: Physical properties: particle size distribution [volume %]

	Loose bulk density [g/ml]	Tapped bulk density [g/ml]	Compressibility [%]	<75 µm	75-150 µm	150-250 µm	250-500 µm	500-710 µm	> 710 µm
1000 RPM	0.39	0.44	11	5.1	6.5	20.7	60.8	6.1	0.2
2000 RPM	0.42	0.47	11	1.8	2.4	9.5	57.3	27	1.5

Example 11

10 Influence of the flow upon addition to crystalliser on the physical properties of the agglomerates.

Two experiments were performed in which all parameters were kept constant, except the flows of the solution and acetone to the crystalliser. In both experiments, a solution of potassium clavulanate was made by dissolving circa 5 kg of potassium clavulanate in 10 l aqueous acetone (acetone:water = 50:50 w/w). This solution, which was kept at 5°C was pumped through a 0.9 mm nozzle to a crystalliser equipped with a high shear mixer and containing 30 l of acetone. Simultaneously, acetone was added to the crystalliser with a volume ratio compared to the solution of circa 21. During the process, the rotational speed of the agitator was 3000 and the temperature was circa 15°C. In the first experiment, the solution flow was 15 l/h and the acetone flow was 312 l/h. In the second experiment, the flows were decreased by a factor 2. Continuously, the suspension was removed from the crystalliser using a pump. The two agglomerated suspensions made were centrifuged, washed with dry acetone and dried in vacuum at 30°C. The physical properties can be seen in Table 4.

Table 4: Physical properties: Particle size distribution [volume %]

	Loose bulk density [g/ml]	Tapped bulk density [g/ml]	Compressibility [%]	<75 µm	75-150 µm	150-250 µm	250-500 µm	500-710 µm	> 710 µm
High flow	0.27	0.36	25	48.7	41.2	9.3	0.3	0	0
Low flow	0.35	0.44	20	48.8	50.4	1.1	0.6	0.4	0

5

Example 12

Influence of the nozzle diameter through which the potassium clavulanate solution is pumped on the physical properties of the agglomerates.

Two experiments were performed in which all parameters were kept constant, except the diameter of the nozzle through which the potassium clavulanate solution is added to the crystalliser. In both experiments, a solution of potassium clavulanate was made by dissolving circa 5 kg of potassium clavulanate in 10 l aqueous acetone (acetone:water = 50:50 w/w). This solution, which was kept at 5°C, was pumped through either a 0.9 mm or 1.2 mm nozzle to a crystalliser equipped with a high shear mixer and containing 50 l of acetone. Simultaneously, acetone was added to the crystalliser with a volume ratio compared to the solution of circa 21. During the process, the rotational speed of the agitator was 3000 and the temperature was circa 15°C. Continuously, the suspension was removed from the crystalliser using a pump. The two agglomerated suspensions made were centrifuged, washed with dry acetone and dried in vacuum at 30°C. The physical properties can be seen in Table 5.

Table 5: Physical properties: particle size distribution [volume %]

Nozzle diameter	Loose bulk density [g/ml]	Tapped bulk density [g/ml]	Compressibility [%]	<75 µm	75-150 µm	150-250 µm	250-500 µm	500-710 µm	> 710 µm
0.9 mm	0.22	0.3	0.27	46.3	43.3	8	1	0.2	0.1
1.2 mm	0.36	0.44	0.18	15.9	50.6	31.3	1.9	0	0.3

CLAIMS

1. Agglomerates in crystalline form comprising one or more β -lactam compounds, wherein at least one β -lactam compound has a high water affinity, and optionally containing one or more excipients, with the proviso that the rosette-like crystalline form of potassium clavulanate is excluded.

5 2. Agglomerates according to claim 1, wherein the agglomerates are substantially free from non-agglomerated β -lactam crystals.

10 3. Agglomerates according to claim 1 or 2, wherein at least one β -lactam compound is clavulanic acid.

15 4. Agglomerates according to any one of the claims 1-3, wherein the β -lactam compound is potassium clavulanate.

20 5. Agglomerates according to claim 4, consisting of only potassium clavulanate.

6. Agglomerates according to claim 4 further comprising amoxicillin.

25 7. Agglomerates according to anyone of the claims 1-4 or 6, wherein the excipients are microcrystalline cellulose, preferably Avicel[®], or silica, preferably Syloid[®] or Aerosil[®].

30 8. Agglomerates according to anyone of the claims 1-7, wherein the agglomerates have an average particle size between about 1 μm and 1500 μm , preferably between about 500 μm and 1500 μm , more preferably between 800 μm and 1200 μm , or preferably between 1 μm and 300 μm , more preferably between 1 μm and 200 μm .

9. Agglomerates according to anyone of the claims 1-8 in sterile form.

10. A process for the preparation of crystallised agglomerates as defined in anyone of the claims 1-9, wherein the agglomerates are produced
5 in a liquid phase by applying stirring devices.

11. A process according to claim 10, wherein the liquid phase comprises a solution or suspension of at least one corresponding β -lactam compound in a solvent or in a mixture of solvents together with one or more
10 anti-solvents.

12. A process according to claim 11, wherein the ratio of the weight of the solution containing β -lactam compound to the anti-solvent is about 0.05 to 10 wt.%.

15 13. A process according to claim 11 or 12, wherein the solvent is selected from the group consisting of water, alcohol, ketone and ester or a mixture thereof, whereby water is present.

20 14. A process according to anyone of the claims 10-13, wherein the anti-solvent is a ketone, like acetone, methylethylketone, methylisobutylketone or an ester, like methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate or an alcohol, like 1-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol or a mixture of these solvents, optionally containing water.

25 15. A process according to anyone of the claims 10-14, wherein one or more stirring devices are used to crystallise, agglomerate and/or deagglomerate the β -lactam compound and optionally classification and blending with excipients and/or another β -lactam compound in a batch or
30 continuous operation, in one or more units.

16. A process according to claim 15, wherein the process is performed by applying stirring devices in one or more vessels, in-line mixers or a combination thereof.

5 17. A process according to claim 15 or 16, wherein a high shear mixer is used as stirring device.

10 18. A process according to anyone of the claims 10-17, characterised by the preparation of agglomerates with various particle sizes, by further using a combination and permutation of different stirring devices and their speed, the type and amount of the solvents used and the way of mixing of one or more solvents and anti-solvents.

15 19. A process according to claim 18, characterised by the preparation of agglomerates with various particle sizes, by further using a nozzle-sprayer for the solution.

20 20. A process according to any one of the claims 10-19, characterised by dissolving one or more corresponding β -lactams in a solvent, adjusting the pH to about neutral and mixing with the anti-solvent.

25 21. A pharmaceutical formulation comprising the agglomerates of anyone of the claims 1-9 and one or more pharmaceutical acceptable excipients.

22. A pharmaceutical formulation comprising amoxicillin, preferably amoxicillin trihydrate and the crystalline agglomerates of potassium clavulanate as defined in claim 5, and optionally one or more pharmaceutically acceptable inert excipients.

-24-

23. A pharmaceutical formulation, comprising a mixture of amoxicillin trihydrate and crystalline agglomerates of potassium clavulanate and one or more pharmaceutically acceptable inert excipients as defined in claim 4.

5 24. Pharmaceutical dosage form comprising a pharmaceutical formulation of anyone of the claims 21-23.

Figure